Pharmacology: Inflammation and Immunopharmacology

Pharmacology: Inflammation and Immunopharmacology — Expert Reference

How it begins

De los AINEs y glucocorticoides clásicos a los inhibidores de checkpoint y la terapia CAR-T: revisión exhaustiva de la farmacología antiinflamatoria, inmunosupresora e inmunomoduladora, con énfasis en mecanismo molecular, correlación clínica y aplicación terapéutica en reumatología, trasplante e inmunooncología.

What it covers

1. Mediators of Inflammation: The Pharmacological Targets
2. The Arachidonic Acid Cascade: The Pharmacological Epicenter
3. Non-Steroidal Anti-Inflammatories (NSAIDs)
4. · 3.1 Classic Non-Selective COX-1/COX-2 NSAIDs
5. · 3.2 Acetylsalicylic Acid (ASA): The Classic NSAID
6. · 3.3 Selective COX-2 Inhibitors (Coxibs)
7. · 3.4 Toxicity of NSAIDs: Systematic Analysis
8. Paracetamol (Acetaminophen): Special Mechanism and Liver Toxicity
9. Systemic Glucocorticoids: Potency, Mechanism and Toxicity
10. · 5.1 Molecular Mechanism of Glucocorticoids
11. · 5.2 Available Systemic Glucocorticoids
12. · 5.3 Adverse Effects of Systemic Glucocorticoids
13. · 5.4 Suppression of the Hypothalamus-Pituitary-Adrenal (HPA) Axis and Withdrawal
14. Pharmacology of Gout and Hyperuricemia
15. · 6.1 Colchicine: The Specific Anti-Inflammatory of Gout
16. · 6.2 Xanthine Oxidase (XO) Inhibitors
17. · 6.3 Uricosurics
18. · 6.4 Recombinant Uricases: Rasburicase and Pegloticase
19. Conventional DMARDs (cDMARDs)
20. · 7.1 Methotrexate (MTX): The Pillar of RA Treatment
21. · 7.2 Hydroxychloroquine (HCQ) and Sulfasalazine (SSZ)
22. · 7.3 Leflunomide and Azathioprine
23. Biological DMARDs (bDMARDs): Targeted Therapy
24. · 8.1 TNF-α Inhibitors: The Most Used Group
25. · 8.2 IL-6 Signaling Inhibitors
26. · 8.3 IL-1 inhibitors
27. · 8.4 Anti-CD20: Rituximab and Successors
28. · 8.5 Abatacept (Orencia®) — CTLA4-Ig costimulation
29. · 8.6 Anti-IL-17 and Anti-IL-23: The Th17 Axis Pathway
30. Synthetic Targeted DMARDs: JAK Inhibitors (JAKinibs)
31. · 9.1 JAK Inhibitors Available: Comparison
32. Immunosuppressants for Solid Organ Transplantation
33. · 10.1 Calcineurin Inhibitors (CNI)
34. · 10.2 mTOR inhibitors
35. · 10.3 Mycophenolate Mofetil (MMF) and Azathioprine
36. · 10.4 Specific Biologicals for Transplantation
37. Immune Checkpoint Inhibitors (ICPi)
38. · 11.1 Anti-PD-1: Nivolumab and Pembrolizumab
39. · 11.2 Anti-PD-L1
40. · 11.3 Anti-CTLA-4: Ipilimumab
41. · 11.4 Immune-related toxicities (irAEs): The Achilles Heel of ICPi
42. H1 and H2 antihistamines
43. · 12.1 First Generation H1 Antihistamines
44. · 12.2 Second Generation H1 Antihistamines
45. Immunomodulators: Stimulate, Balance or Suppress
46. · 13.1 Thalidomide, Lenalidomide and IMiDs
47. · 13.2 Intravenous Immunoglobulin (IVIG)
48. · 13.3 Therapeutic Interferons
49. · 13.4 Colony Stimulating Factors: G-CSF and GM-CSF
50. Pharmacology of Anaphylaxis
51. Relevant Drug Interactions
52. Glossary of Key Terms
53. Select Reference Bibliography
54. · Fundamental Texts
55. · Clinical Guidelines
56. · Seminal Articles